Literature DB >> 27343741

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.

Sean A Virani1, Susan Dent2, Christine Brezden-Masley3, Brian Clarke4, Margot K Davis5, Davinder S Jassal6, Christopher Johnson7, Julie Lemieux8, Ian Paterson9, Igal A Sebag10, Christine Simmons5, Jeffrey Sulpher2, Kishore Thain11, Paaldinesh Thavendiranathan12, Jason R Wentzell13, Nola Wurtele5, Marc André Côté14, Nowell M Fine15, Haissam Haddad16, Bradley D Hayley17, Sean Hopkins18, Anil A Joy9, Daniel Rayson19, Ellamae Stadnick20, Lynn Straatman5.   

Abstract

Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morbidity and mortality among cancer survivors. This guideline, authored by a pan-Canadian expert group of health care providers and commissioned by the Canadian Cardiovascular Society, is intended to guide the care of cancer patients with established cardiovascular disease or those at risk of experiencing toxicities related to cancer treatment. It includes recommendations and important management considerations with a focus on 4 main areas: identification of the high-risk population for cardiotoxicity, detection and prevention of cardiotoxicity, treatment of cardiotoxicity, and a multidisciplinary approach to cardio-oncology. All recommendations align with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Key recommendations for which the panel provides a strong level of evidence include: (1) that routine evaluation of traditional cardiovascular risk factors and optimal treatment of preexisting cardiovascular disease be performed in all patients before, during, and after receiving cancer therapy; (2) that initiation, maintenance, and/or augmentation of antihypertensive therapy be instituted per the Canadian Hypertension Educational Program guidelines for patients with preexisting hypertension or for those who experience hypertension related to cancer therapy; and (3) that investigation and management follow current Canadian Cardiovascular Society heart failure guidelines for cancer patients who develop clinical heart failure or an asymptomatic decline in left ventricular ejection fraction during or after cancer treatment. This guideline provides guidance to clinicians on contemporary best practices for the cardiovascular care of cancer patients.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27343741     DOI: 10.1016/j.cjca.2016.02.078

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  54 in total

Review 1.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.

Authors:  Hui-Ming Chang; Tochukwu M Okwuosa; Tiziano Scarabelli; Rohit Moudgil; Edward T H Yeh
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

Review 2.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.

Authors:  Hui-Ming Chang; Rohit Moudgil; Tiziano Scarabelli; Tochukwu M Okwuosa; Edward T H Yeh
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

3.  Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada.

Authors:  Moira Rushton; Isac Lima; Meltem Tuna; Chris Johnson; Josee Ivars; Kathy Pritchard; Steven Hawken; Susan Dent
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

4.  Looking beyond cancer for cabozantinib-induced cardiotoxicity: evidence of absence or absence of evidence?

Authors:  Eugenia Y Lee; Andrew T Yan
Journal:  Ann Transl Med       Date:  2019-07

Review 5.  A Cardio-Oncology Data Commons: Lessons from Pediatric Oncology.

Authors:  Anant Mandawat; Logan Eberly; William Border
Journal:  Curr Cardiol Rep       Date:  2019-09-13       Impact factor: 2.931

Review 6.  Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.

Authors:  Sonu S Varghese; Cameron R Eekhoudt; Davinder S Jassal
Journal:  Mol Cell Biochem       Date:  2021-04-09       Impact factor: 3.396

Review 7.  Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.

Authors:  Giuseppe Curigliano; Evandro de Azambuja; Daniel Lenihan; Maria Grazia Calabrò; Daniela Cardinale; Carlo Maria Cipolla
Journal:  Oncologist       Date:  2019-05-07

Review 8.  Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.

Authors:  Peggy M Kostakou; Nikos T Kouris; Vassilios S Kostopoulos; Dimitrios S Damaskos; Christoforos D Olympios
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 9.  Modern concepts in cardio-oncology.

Authors:  Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

10.  Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Authors:  G Curigliano; D Lenihan; M Fradley; S Ganatra; A Barac; A Blaes; J Herrmann; C Porter; A R Lyon; P Lancellotti; A Patel; J DeCara; J Mitchell; E Harrison; J Moslehi; R Witteles; M G Calabro; R Orecchia; E de Azambuja; J L Zamorano; R Krone; Z Iakobishvili; J Carver; S Armenian; B Ky; D Cardinale; C M Cipolla; S Dent; K Jordan
Journal:  Ann Oncol       Date:  2020-02       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.